Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20,000 units/day) in the treatment of patients with acute coronary event--first year and long-term comparative mortality.
作者信息
Sayen J J, Singer R B, Peirce G, Horwitz O
出版信息
Trans Am Clin Climatol Assoc. 1983;94:141-53.
Abstract
摘要
相似文献
1
2
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Eur Heart J. 1999 Nov;20(22):1657-66. doi: 10.1053/euhj.1999.1750.
3
[Analgesic action of subcutaneous heparin therapy of stenocardia].
Clin Ter. 1972 Aug 15;62(3):225-38.
4
Effectiveness of anticoagulants.
Semin Thromb Hemost. 1986 Jan;12(1):21-37. doi: 10.1055/s-2007-1003532.
5
6
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702.
7
[The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
Arq Bras Cardiol. 1995 Dec;65(6):475-8.
8
[Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
Rev Med Chil. 1998 Mar;126(3):259-64.
9
Short-term (28 days) prognosis between genders according to the type of coronary event (Q-wave versus non-Q-wave acute myocardial infarction versus unstable angina pectoris).
Am J Cardiol. 2004 Nov 1;94(9):1161-5. doi: 10.1016/j.amjcard.2004.07.084.
10
[Heparin therapy in coronary disease].
Dtsch Med Wochenschr. 1992 Jan 3;117(1):35-6.
引用本文的文献
1
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.
Nat Commun. 2017 Sep 11;8(1):503. doi: 10.1038/s41467-017-00568-7.
2
Heparin versus placebo for non-ST elevation acute coronary syndromes.
Cochrane Database Syst Rev. 2014 Jun 27;2014(6):CD003462. doi: 10.1002/14651858.CD003462.pub3.
3
Heparin for oral use: preliminary studies.
Trans Am Clin Climatol Assoc. 1993;104:94-102; discussion 102-3.
本文引用的文献
1
PHYSIOLOGIC ACTIONS OF HEPARIN NOT RELATED TO BLOOD CLOTTING.
Am J Cardiol. 1964 Jul;14:18-24. doi: 10.1016/0002-9149(64)90099-2.
2
Initial myocardial infarction among 503 veterans: five-year survival.
Am J Med. 1960 Jun;28:871-83. doi: 10.1016/0002-9343(60)90196-0.
3
Heparin versus heparin-bishydroxycoumarin anticoagulant therapy: comparison in patients with acute complicated myocardial infarction.
JAMA. 1960 Oct 29;174:1157-60. doi: 10.1001/jama.1960.03030090013003.
4
Effect of heparin on lipemia-induced angina pectoris.
J Am Med Assoc. 1957 Mar 2;163(9):727-31. doi: 10.1001/jama.1957.02970440023007.
5
Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin.
Circ Res. 1980 May;46(5):625-34. doi: 10.1161/01.res.46.5.625.
6
Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth.
J Cell Biol. 1981 Aug;90(2):372-9. doi: 10.1083/jcb.90.2.372.
7
Heparin necrosis: an anticoagulant-induced cutaneous infarct.
J Am Acad Dermatol. 1982 Nov;7(5):674-7. doi: 10.1016/s0190-9622(82)70150-1.
8
Heparin effect on blood viscosity.
Clin Cardiol. 1982 Mar;5(3):215-8. doi: 10.1002/clc.4960050303.
9
Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
N Engl J Med. 1982 Jan 28;306(4):189-94. doi: 10.1056/NEJM198201283060401.
10
Heparin-induced hypoaldosteronism. Report of a case.
JAMA. 1981 Nov 13;246(19):2189-90.
Zotero 插件